|
|
|
市場調查報告書
以藥劑開發研究為目的的生物標記，實驗，與動向
Biomarkers, Tests and Trends for Drug R&D
|
以藥劑開發研究為目的的生物標記，實驗，與動向 是由出版商Takeda Pacific在2010年02月所出版的。
這份英文市場調查報告書包含144 pages 價格從美金2195起跳。
本報告書為，生物標記相關的研究開發動向，投資以及M&A，企業合作，技術服務動向等等的檢驗，並且預測到2014年為止的投資動向，概述如下。
第1章 以藥劑開發研究為目的的生物標記市場
- 藥品業界的研究開發費與新產品
- 安全性、効果、未滿足的需求
- 生物標記新藥製作工具
- 個別化醫療
- 基因藥理學組學生物標記
- 市場生態系
第2章 以藥劑開發研究為目的的生物標記
- 生物標記定義
- 生物標記、分析、實驗
- 生物標記所造成的業界
- 生物標記開發
第3章 生物標記研究開発における提携とM&A
第4章 生物標記技術與藥劑研究開發
第5章 市場規模與觀察預測
第6章 進行生物標記研究開發的主要企業
- Abbott Molecular
- Affymetrix, Inc.
- Asuragen, Inc.
- Beckman Coulter, Inc.
- bioMerieux SA
- Celera Corporation
- Cepheid
- Dako A/S
- Epigenomics AG
- Expression Analysis, Inc.
- Gen-Probe, Inc.
- Helicos Biosciences Corporation
- Hologic, Inc.
- Illumina, Inc.
- Ingenuity Systems, Inc.
- KineMed
- LabCorp
- Life Technologies, Inc.
- Luminex Corporation
- Nanosphere, Inc.
- Nymox Pharmaceutical Corporation
- Orion Genomics LLC
- QIAGEN N.V.
- Quest Diagnostics, Inc.
- Rules-Based Medicine, Inc.
- Sequenom, Inc.
- 454 Life Sciences (Roche)
- Banyan Biomarkers, Inc.
- Combimatrix Molecular Diagnostics, Inc.
- Protagen AG
- Singulex
第7章 動向與將來的方向性
第8章 附錄
Abstract
This report is about the world market for biomarkers and tests used for drug
R&D. The study reviews and analyzes the market by examining biomarker related
drug R&D spending, trends, major diseases, applications, M&As, alliances,
tools & technologies, products and R&D services. This report provides a
detailed outlook of the market for biomarkers and related genomic, proteomic,
or other tests used in drug R&D programs. The research report also touches on
metabolomic and imaging biomarkers. This study sizes the world market and
growth rate of biomarkers and tests for drug R&D spending to 2014.
The major drug makers face many daunting challenges that are being mitigated
by the companies using key business and technical strategies that utilize
biomarkers. Despite the recent severe recession, this business area is set
for strong continued double-digit growth as biomarkers and tests in
drug/therapeutic R&D enable emerging opportunities, potentially worth billions
of dollars.
This business report updates our current view about biomarkers for drug R&D.
The study discusses ongoing government initiatives that foster worldwide
development in biomarkers and personalized medicine opportunities. Their
expectation is to streamline commercializing new, safer, drugs and
co-developed companion predictive tests by integrating biomarkers and
pharmacogenomic (PGx) tests into the critical path of drug R&D. The study
discusses how clinical trials are undergoing important emerging changes that
integrate biomarkers and assays into the drug development process to provide
more useful information in order for drug makers to make better product
development decisions.
This study uses more than 51 figures and tables to illustrate its insightful
findings. The report offers detailed information including data tables about
key technologies, M&As, alliances and so on. More than thirty selected
companies are profiled with details such as contact information, business
overview, financial details and product information. This report uses
hyperlinks to help readers jump to Table of Content items or to text-linked
Internet sites.
This must-have report would benefit people with job titles including CEO, VPs,
Director of Business Development, Research Directors, Entrepreneurs, Venture
Capitalists, Investment Planners, Research Scientists, Consultants or Industry
Analysts.
About Takeda Pacific
Analysts at Takeda Pacific developed this report. The company provides
business consulting that focuses on facilitating business development and
market research projects. The business projects may involve European, Japanese
and North American Life Science companies. Since it' s founding in late 1992,
TP has reviewed or analyzed thousands of life Science and technology firms for
its clients.
Since 1992, Takeda Pacific has produced numerous industry reports about
emerging pharma, biotech, medical devices and technology companies and
markets. Takeda Pacific also offers follow-up consulting or custom research
consulting to assist in your business development or benchmarking, market
assessment projects.
Report Statistics
- Authors: Jay K. Myers, Paula Mitchell Myers
- Publication Date: February 2010
- Number of Pages: 144 pages; can be printed; fully searchable PDF format.
Table of Contents
1.Biomarker Market for Drug R&D
- Drug Industry R&D Spending and New Products
- Limited Drug Safety, Effectiveness and Unmet Medical
- Needs
- Common Drug Types Are Not Very Effective
- Drug-Related Adverse Events (AEs) Create Health
- Risks for Large Patient Populations
- Key Unmet Medical Needs
- Tools for Biomarker Discovery and Qualification
- Enables Personalized Medicine
- Pharmacogenomic and ‘Omic Biomarkers
- Government, Biomarkers and PGx
- Market Ecosystem
2.Biomarkers For Drug R&D
- Definitions of What Biomarkers Are
- Healthcare and Biomarkers
- The Definition of Biomarkers Continues to Evolve
- The FDA' s Definitions of Biomarkers and Tests for
- Updated Definitions And Biomarker Qualification
- FDA' s International Harmonization Progress
- Biomarkers, Assays and Tests
- Nucleic Acids, Proteins, Profiles and Metabolites
- Pharmacogenomic (PGx) Biomarkers and Personalized
- New Clinical Trial Designs and Patient
- Drug-Test Synergies for Rx/ Dx Companion Tests
- Biomarkers Generate Industry Buzz
- FDA' s Biomarker Activities
- FDA vXDS Program and International Harmonization
- Other Government Initiatives in Personalized
- SNPs, CNVs, Haplotyping, Molecular Patterns and
- Gene Expression Profiles Measure Complex
- Diseases
- The Goal to Drive Down the Cost of SNP Tests
- MicroRNAs are Biomarkers; shRNAs Can Screen for
- Multiplexed Protein Patterns Can Be Biomarkers
- Developing Biomarkers, Assays and Dx
3.Alliances and M&As in Biomarker R&D
- Alliances in Biomarkers and Drug R&D
- Alliances in Biomarkers By Major Diseases
- Alliance Deals to Mid-2007
4.Technologies for Biomarkers and Drug R&D
- PGx Tests for Drug R&D
- Biomarker Testing and Analysis Technologies
- Genomic Biomarker Testing
- Direct Detection with Blots and ELISAs
- PCR-based Target Amplification Technology
- Non-PCR Target Amplification and Signal
- Signal Amplification
- Microarrays and Microfluidic Systems
- Microarrays
- Microfluidic Systems (Lab-on-a-chips)
- First-, Second- and Third-Generation DNA Sequencing
- Proteomic Biomarker Testing
- Metabolomics Biomarker Testing
- Imaging Biomarker Testing
- Bioinformatic Software is Key to Biomarker Analysis
5.Market Size and Outlook for Drug Industry Biomarker R&D
- Spending
- Global Drug Makers' Biomarker R&D Spending Trends
- Global Drug Makers' Biomarker R&D Spending Market
- Shares
- Global Drug Makers' Biomarker R&D Market Size by
- Global Drug Makers' Biomarker R&D Market Size by
- Application/ Clinical Phase
- Global Drug Makers' Biomarker R&D by Tools and
- Drug Makers' Biomarker R&D Spending by World Region
6.Selected Companies Working in Biomarker R&D
- Abbott Molecular
- Affymetrix, Inc.
- Asuragen, Inc.
- Beckman Coulter, Inc.
- bioMerieux SA
- Celera Corporation
- Cepheid
- Dako A/S
- Epigenomics AG
- Expression Analysis, Inc.
- Gen-Probe, Inc.
- Helicos Biosciences Corporation
- Hologic, Inc.
- Illumina, Inc.
- Ingenuity Systems, Inc.
- KineMed
- LabCorp
- Life Technologies, Inc.
- Luminex Corporation
- Nanosphere, Inc.
- Nymox Pharmaceutical Corporation
- Orion Genomics LLC
- QIAGEN N.V.
- Quest Diagnostics, Inc.
- Rules-Based Medicine, Inc.
- Sequenom, Inc.
- 454 Life Sciences (Roche)
- Banyan Biomarkers, Inc.
- Combimatrix Molecular Diagnostics, Inc.
- Protagen AG
- Singulex
7.Trends and Future Directions
- Biomarkers for Drug R&D
- Government Initiatives Foster Drug R&D + Biomarker/
- Biomarkers, a Key Opportunity on the Critical Path
- The Critical Path Linked to FDA' s VXDS Program
- Biomarkers Enable New Clinical Trial Designs
- Future Direction of PGx Tests and Targeted Therapies
- Personalized Medicine is Here and is Set for Growth
- Cancer Biomarkers and Tests
- Future Direction for CNS Disease Tests
- Infectious Disease Testing
8.Appendices
- WW Populations by Diseases
- Examples of Uses of Biomarker Tests for Drug R&D
- Clinical PGx Biomarker Tests in the Drug R&D Paths
- Biomarker Tests for Drug R&D
- Links to Organizations Mentioned in this Report
- About Takeda Pacific
- About the Authors
List of Tables
- Table 1. Annual Drug R&D Spending Estimates
- Table 2. Common Drug Types and Low Drug Response Rates (%)
- Table 3. Large Disease Populations with Unmet Medical Need
- Table 4. Areas of Drug R&D Interest for vXDSs Sent to FDA
- Table 5. Examples of Biomarker Topics For FDA vXDS
- Table 6. Path to Commercialize Biomarker Tests
- Table 7. Summary of Alliances in Biomarker Pharma-Biotech
- Table 8. Alliances in Biomarkers and Pharma-Biotech R&D by
- Table 9. Analysis of the ‘Others’ (Drug Response) Biomarker
- Alliances By Indication/ Application
- Table 10. Key Alliances in Biomarkers and Pharma-Biotech
- R&D by Major Disease and Indication/ Application, 1H/2007
- Table 11. Key Alliances in Biomarkers and Pharma-Biotech
- R&D by Major Disease and Indication/ Application, 2006
- Table 12. Key Alliances in Biomarkers and Pharma-Biotech
- R&D by Major Disease and Indication/ Application, 2005
- Table 13. Target Amplification Technologies
- Table 14. Target Signal Amplification Technologies
- Table 15. Microarray and Lab-on-a-chip Technologies
- Table 16. First-, Second- and Third-Generation DNA
- Table 17. Proteomic Technologies for Biomarker Testing or R&D
- Table 18. Metabolomic Technologies and Biomarkers
- Table 19. Global Drug Makers' Biomarker R&D Spending by Major Diseases or
Applications to 2014
- Table 20. Global Drug Makers' Biomarker R&D Spending Market Shares by
Disease, 2008 & 2014
- Table 21. Global Drug Makers' Biomarker R&D by Application/Clinical Phase
- Table 22. Global Drug Makers' Biomarker R&D Spending by Tools and
Services, 2008-2014
- Table 23. Global Drug Makers' Biomarker R&D Spending by Region
- Table 24. Six Major FDA Critical Path Topics
- Table 25. Future Direction of PGx Tests
- Table 26. Future Direction for Risk Prediction Genetic Tests
- Table 27. Highlights of Biomarkers, Targeted Therapies, and Tests (PGx)
- Table 28. Cancer Companion Tests and Targeted Therapies
- Table 29. Future Direction of Cancer Companion Tests
- Table 30. CNS Tests Likely in Five Years
- Table 31. Future Direction of Infectious Disease Tests
- Table 32. Major Diseases by Mortality, Incidence and Prevalence
- Table 33. Top Health Risk Factors Leading to Death in the Developed World
- Table 34. Path For Prediction of Drug Response Safety Risk
- Table 35. Path For Drug Efficacy Testing v. Disease State
- Table 36. Summary of PGx Biomarker Test Focus in Drug R&D
- Table 37. Weblinks to Companies Mentioned in this Report
- Table 38. Weblinks to Selected Government Organizations
- Table 39. Weblinks to Biomarker Consortium Industry Members
- Table 40. Weblinks to Biomarker Consortium Non-Profit Members
List of Illustrations
- Figure 1. The Biomarker Pharma/ Biotech R&D/ PGx Market Ecosystem
- Figure 2. Microarrays and Microfluidic Chips Used in Drug R&D
- Figure 3. Affymetrix Microarray System
- Figure 4. A Microfluidics Instrument for Drug R&D
- Figure 5. Diagram of a Protein Capture Microarray
- Figure 6. Analytical Software
- Figure 7. Global Drug Makers' R&D Spending by Major Diseases to 2014
- Figure 8. Global Drug Makers' Biomarker R&D Spending Market Shares by
Disease, 2008 & 2014
- Figure 9. Global Drug Makers' Biomarker R&D by Application/ Clinical Phase
- Figure 10. Global Drug Makers' Biomarker R&D Spending by Tools and
Services, 2008-2014
- Figure 11. Global Drug Makers' Biomarker R&D Spending by Region
- Figure 12. Biomarkers and the FDA Critical Path
|
 |
